New combo therapy shows early promise for hard-to-treat colorectal cancer

This early-stage study tested whether adding two drugs (romidepsin and 5-azacitidine) to an immunotherapy (MK-3475) could help shrink tumors in people with a type of advanced colorectal cancer that usually doesn't respond to immunotherapy. 27 adults with microsatellite stable (MSS) colorectal cancer who had already tried standard treatments took part. The main goals were to check safety and see if the combination increased immune cells in the tumors.